Advanced Oncology Medicines Export Hormone Therapy, Hematology, CAR-T, Cell Therapy & Radiopharmac
₹ 4,000/PieceTreatment Type: Testosterone Replacement Therapy
Usage/Application: Menopause
Advanced Oncology Medicines Export | Hormone Therapy, Hematology, CAR-T, Cell Therapy Radiopharmaceuticals
Important hormonal and endocrine anticancer medicines include Abiraterone, Anastrozole, Apalutamide, Bicalutamide, Darolutamide, Degarelix, Enzalutamide, Exemestane, Fulvestrant, Goserelin, Letrozole, Leuprolide, Megestrol, Nilutamide, Relugolix, Tamoxifen and Toremifene. Major hematology and multiple-myeloma medicines include Bortezomib, Carfilzomib, Ixazomib, Lenalidomide, Pomalidomide, Thalidomide, Selinexor, Venetoclax, Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib, Asciminib, Gilteritinib, Midostaurin, Quizartinib, Revumenib, Olutasidenib, Enasidenib, Ivosidenib, Nirogacestat and Plerixafor.
Important cell and gene therapies include Tisagenlecleucel, Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, Lisocabtagene Maraleucel, Idecabtagene Vicleucel, Ciltacabtagene Autoleucel, Obecabtagene Autoleucel, Afamitresgene Autoleucel and Lifileucel. Emerging oncology platforms include CAR-T, CAR-NK, TCR-T, tumor-infiltrating lymphocyte therapy, engineered T-cell therapy and next-generation cellular immunotherapy.
Major radiopharmaceutical and targeted radionuclide oncology molecules include Iobenguane I-131, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Radium-223 dichloride, Yttrium-90 ibritumomab tiuxetan and Iodine-131-based cancer therapies. Emerging radioligand searches include PSMA radioligand therapy, Lu-177 PSMA, actinium-225 PSMA, alpha-particle therapy, targeted radionuclide therapy and radiopharmaceutical oncology export.
Additional oncology molecules and classes include Proteasome Inhibitors, PARP Inhibitors, BCL-2 Inhibitors, EZH2 Inhibitors, PI3K Inhibitors, mTOR Inhibitors, CDK4/6 Inhibitors, HDAC Inhibitors, BET Inhibitors, LSD1 Inhibitors, DNA Damage Response Inhibitors and Molecular Glue/Protein Degrader therapies.
Important clinical-stage and emerging oncology areas include KRAS G12D inhibitors, KRAS G12C inhibitors, pan-KRAS inhibitors, next-generation PARP inhibitors, ATR inhibitors, WEE1 inhibitors, CHK1 inhibitors, PRMT5 inhibitors, MDM2 inhibitors, menin inhibitors, molecular glue degraders, PROTAC oncology drugs, next-generation radioligands, bispecific antibodies, trispecific antibodies, cancer vaccines and personalized cellular therapies. These are included for clinical research, CRO and pharmaceutical-development searches and should not be treated as universally approved or commercially available.
High-value export keywords include oncology drug exporter, cancer medicine exporter, anticancer pharmaceutical supplier, cancer injection supplier, chemotherapy exporter, targeted therapy exporter, immunotherapy exporter, oncology biologics supplier, monoclonal antibody exporter, ADC supplier, bispecific antibody exporter, CAR-T therapy, radiopharmaceutical exporter, clinical trial oncology supply and international cancer medicine sourcing.